{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:26:37Z","timestamp":1789597597348,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This critical review explores current and emerging strategies for the management of open-angle glaucoma (OAG), highlighting pharmacological, laser-based, and surgical innovations. It aims to synthesize recent evidence, assess real-world applicability, and evaluate future directions in personalized glaucoma care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and Cochrane Library databases for English-language publications between January 2000 and May 2025. Studies on first-line therapies, combination treatments, microinvasive glaucoma surgery (MIGS), laser modalities, and novel drug delivery systems were included. The review presents an overview of significant advancements and future directions in glaucoma treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Prostaglandin analogs remain the cornerstone of medical therapy, while fixed combinations and sustained-release implants improve adherence. Selective laser trabeculoplasty (SLT) has gained traction as a first-line treatment in mild OAG, though its effectiveness in advanced stages is limited. MIGS procedures are increasingly used as safer alternatives to traditional surgery, especially when combined with cataract extraction. Affordable goniotomy techniques and suprachoroidal approaches offer promising solutions in resource-constrained settings. Neuroprotection, vascular modulation, and caspase inhibition represent future adjunctive strategies. In Romania, glaucoma remains a major public health challenge, with limited treatment coverage and delayed diagnoses due to systemic gaps in education and screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Management of OAG is shifting toward patient-centered interventions that balance efficacy, safety, and accessibility. Continued integration of novel therapies, surgical innovation, and real-world cost-effectiveness data is essential for optimizing treatment algorithms, particularly in under-resourced health systems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-025-03773-2","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T05:28:38Z","timestamp":1758691718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["New trends in the treatment of open-angle glaucoma: a critical review"],"prefix":"10.1007","volume":"45","author":[{"given":"Aigean","family":"Bilal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu","family":"Chirila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Hangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"3773_CR1","volume-title":"Ophthalmology","author":"M Yanoff","year":"2009","unstructured":"Yanoff M, Duker JS, Augsburger JJ (2009) Ophthalmology. Mosby Elsevier"},{"key":"3773_CR2","unstructured":"Salmon JF (2019) Kanski\u2019s Clinical Ophthalmology E-Book: A Systematic Approach. Elsevier Health Sciences"},{"key":"3773_CR3","volume-title":"Tratat De Oftalmologie","author":"M Dumitrache","year":"2012","unstructured":"Dumitrache M (2012) Tratat De Oftalmologie. Editura Universitara \u201cCarol Davila\u201d Bucuresti, Bucuresti"},{"key":"3773_CR4","unstructured":"Turbert D (2024) Get an eye disease screening at 40. In: American Academy of Ophthalmology. https:\/\/www.aao.org\/newsroom\/news-releases\/detail\/early-detection-key-to-slowing-progression-of-glau. Accessed 22 Sept 2025"},{"key":"3773_CR5","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0886-3350(00)00567-8","volume":"26","author":"SA Obstbaum","year":"2000","unstructured":"Obstbaum SA (2000) The lens and angle-closure glaucoma. J Cataract Refract Surg 26:941\u2013942","journal-title":"J Cataract Refract Surg"},{"key":"3773_CR6","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1442-9071.2009.01920.x","volume":"36","author":"N Niyadurupola","year":"2008","unstructured":"Niyadurupola N, Broadway DC (2008) Pigment dispersion syndrome and pigmentary glaucoma\u2013a major review. Clin Exp Ophthalmol 36:868\u2013882","journal-title":"Clin Exp Ophthalmol"},{"key":"3773_CR7","doi-asserted-by":"crossref","unstructured":"Farah SC, Constantin AE, Radu BM (2021) Stress in glaucoma, from theory to practice","DOI":"10.31688\/ABMU.2021.56.1.17"},{"key":"3773_CR8","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B et al (2002) Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120:1268\u20131279","journal-title":"Arch Ophthalmol"},{"key":"3773_CR9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","volume":"123","author":"T Li","year":"2016","unstructured":"Li T, Lindsley K, Rouse B et al (2016) Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology 123:129\u2013140","journal-title":"Ophthalmology"},{"key":"3773_CR10","volume-title":"Shields\u2019 textbook of glaucoma","author":"RR Allingham","year":"2020","unstructured":"Allingham RR, Moroi S, Shields MB, Damji K (2020) Shields\u2019 textbook of glaucoma. Lippincott Williams & Wilkins"},{"key":"3773_CR11","doi-asserted-by":"crossref","unstructured":"Vass C, Hirn C, Sycha T, et al (2007) Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Datab Syst Rev","DOI":"10.1002\/14651858.CD003167.pub3"},{"key":"3773_CR12","unstructured":"National Institute for Health and Care Excellence (NICE) (2017) Recommendations | Glaucoma: diagnosis and management | Guidance | NICE. https:\/\/www.nice.org.uk\/guidance\/ng81\/chapter\/Recommendations. Accessed 12 May 2024"},{"key":"3773_CR13","first-page":"417","volume":"312","author":"A Bill","year":"1989","unstructured":"Bill A (1989) Uveoscleral drainage of aqueous humor: physiology and pharmacology. Prog Clin Biol Res 312:417\u2013427","journal-title":"Prog Clin Biol Res"},{"key":"3773_CR14","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1167\/iovs.05-0516","volume":"47","author":"D-J Oh","year":"2006","unstructured":"Oh D-J, Martin JL, Williams AJ et al (2006) Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest Ophthalmol Vis Sci 47:953\u2013963","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3773_CR15","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1001\/archopht.124.10.1472","volume":"124","author":"R Rachmiel","year":"2006","unstructured":"Rachmiel R, Trope GE, Chipman ML et al (2006) Effect of medical therapy on glaucoma filtration surgery rates in Ontario. Arch Ophthalmol 124:1472\u20131477","journal-title":"Arch Ophthalmol"},{"key":"3773_CR16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00061198-200312000-00003","volume":"12","author":"K Hedman","year":"2003","unstructured":"Hedman K, Alm A, Gross RL (2003) Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J Glaucoma 12:463\u2013465","journal-title":"J Glaucoma"},{"key":"3773_CR17","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.ajo.2003.10.034","volume":"137","author":"GF Schwartz","year":"2004","unstructured":"Schwartz GF, Reardon G, Mozaffari E (2004) Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 137:S13\u2013S16","journal-title":"Am J Ophthalmol"},{"key":"3773_CR18","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/S0039-6257(99)00107-1","volume":"44","author":"K Sall","year":"2000","unstructured":"Sall K, Group BPTS (2000) The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt\u00ae) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Surv Ophthalmol 44:S155\u2013S162","journal-title":"Surv Ophthalmol"},{"key":"3773_CR19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","volume":"151","author":"T Krupin","year":"2011","unstructured":"Krupin T, Liebmann JM, Greenfield DS et al (2011) A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 151:671\u2013681","journal-title":"Am J Ophthalmol"},{"key":"3773_CR20","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14656566.2014.936850","volume":"15","author":"G Holl\u00f3","year":"2014","unstructured":"Holl\u00f3 G, Topouzis F, Fechtner RD (2014) Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother 15:1737\u20131747","journal-title":"Expert Opin Pharmacother"},{"key":"3773_CR21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191185","volume":"13","author":"S Frech","year":"2018","unstructured":"Frech S, Kreft D, Guthoff RF, Doblhammer G (2018) Pharmacoepidemiological assessment of adherence and influencing co-factors among primary open-angle glaucoma patients\u2014an observational cohort study. PLoS ONE 13:e0191185","journal-title":"PLoS ONE"},{"key":"3773_CR22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/jop.2018.0067","volume":"35","author":"JR Seal","year":"2019","unstructured":"Seal JR, Robinson MR, Burke J et al (2019) Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues. J Ocul Pharmacol Ther 35:50\u201357","journal-title":"J Ocul Pharmacol Ther"},{"key":"3773_CR23","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S506520","author":"I Vagiakis","year":"2025","unstructured":"Vagiakis I, Papadopoulou EP, Amaxilati E et al (2025) Bimatoprost intracameral implant (Durysta\u00ae): a new era in glaucoma management through sustained-release innovation. Drug Des Devel Ther. https:\/\/doi.org\/10.2147\/DDDT.S506520","journal-title":"Drug Des Devel Ther"},{"key":"3773_CR24","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S515166","author":"E Chatzimichail","year":"2025","unstructured":"Chatzimichail E, Christodoulaki E, Konstas PA et al (2025) Rho kinase inhibitors in glaucoma management: current perspectives and future directions. Drug Des Devel Ther. https:\/\/doi.org\/10.2147\/DDDT.S515166","journal-title":"Drug Des Devel Ther"},{"key":"3773_CR25","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S154001","author":"L Dasso","year":"2018","unstructured":"Dasso L, Al-Khaled T, Sonty S, Aref AA (2018) Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date. Clin Ophthalmol. https:\/\/doi.org\/10.2147\/OPTH.S154001","journal-title":"Clin Ophthalmol"},{"key":"3773_CR26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E et al (2018) Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol 186:116\u2013127","journal-title":"Am J Ophthalmol"},{"key":"3773_CR27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/ph18040523","volume":"18","author":"JK Tan","year":"2025","unstructured":"Tan JK, Khaw PT, Henein C (2025) Rho kinase (ROCK) inhibitors in the treatment of glaucoma and glaucoma surgery: a systematic review of early to late phase clinical trials. Pharmaceuticals 18:523","journal-title":"Pharmaceuticals"},{"key":"3773_CR28","unstructured":"Aerie Pharmaceuticals Reports RoclatanTM Phase 2b Results Achieve All Clinical Endpoints | Fierce Biotech. https:\/\/www.fiercebiotech.com\/biotech\/aerie-pharmaceuticals-reports-roclatantm-phase-2b-results-achieve-all-clinical-endpoints. Accessed 18 May 2024"},{"key":"3773_CR29","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1177\/11206721211008783","volume":"31","author":"M Batra","year":"2021","unstructured":"Batra M, Gupta S, Nair AB et al (2021) Netarsudil: a new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension. Eur J Ophthalmol 31:2237\u20132244","journal-title":"Eur J Ophthalmol"},{"key":"3773_CR30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4103\/sjopt.sjopt_201_24","volume":"38","author":"R Kumari","year":"2024","unstructured":"Kumari R, Saha BC, Ambasta A, Kumar VB (2024) Short-term safety and efficacy of ripasudil as \u201cadd-on therapy\u201d in glaucoma patients on maximum tolerable glaucoma medication. Saudi J Ophthalmol 38:343\u2013347","journal-title":"Saudi J Ophthalmol"},{"key":"3773_CR31","unstructured":"Roach L (2016) On the Horizon: New Treatments for Glaucoma. In: American Academy of Ophthalmology. https:\/\/www.aao.org\/eyenet\/article\/on-horizon-new-treatments-glaucoma. Accessed 18 May 2024"},{"key":"3773_CR32","unstructured":"Stuart A (2018) Drug Update: Vyzulta and Rhopressa. In: American Academy of Ophthalmology. https:\/\/www.aao.org\/eyenet\/article\/drug-update-vyzulta-and-rhopressa. Accessed 19 May 2024"},{"key":"3773_CR33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/IJG.0000000000002520","volume":"34","author":"\u00d6 \u00d6zer","year":"2025","unstructured":"\u00d6zer \u00d6, Baysal Z, Bi\u00e7er GY, Do\u011fan L (2025) The effect of latanoprostene bunod 0.024% on optical coherence tomography angiography in newly diagnosed open angle glaucoma. J Glaucoma 34:224\u2013231","journal-title":"J Glaucoma"},{"key":"3773_CR34","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.2147\/OPTH.S156038","volume":"12","author":"VM Addis","year":"2018","unstructured":"Addis VM, Miller-Ellis E (2018) Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy. Clin Ophthalmol 12:2649\u20132657. https:\/\/doi.org\/10.2147\/OPTH.S156038","journal-title":"Clin Ophthalmol"},{"key":"3773_CR35","doi-asserted-by":"crossref","unstructured":"Beidoe G, Mousa SA (2012) Current primary open-angle glaucoma treatments and future directions. Clin Ophthalmol 1699\u20131707","DOI":"10.2147\/OPTH.S32933"},{"key":"3773_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-11-1","volume":"11","author":"JH Fang","year":"2010","unstructured":"Fang JH, Wang XH, Xu ZR, Jiang FG (2010) Neuroprotective effects of bis (7)-tacrine against glutamate-induced retinal ganglion cells damage. BMC Neurosci 11:1\u20139","journal-title":"BMC Neurosci"},{"key":"3773_CR37","first-page":"1288","volume":"14","author":"RD Steigerwalt","year":"2008","unstructured":"Steigerwalt RD, Gianni B, Paolo M et al (2008) Effects of Mirtogenol on ocular blood flow and intraocular hypertension in asymptomatic subjects. Mol Vis 14:1288\u20131292","journal-title":"Mol Vis"},{"key":"3773_CR38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3109\/02713683.2010.489728","volume":"35","author":"M-L Ko","year":"2010","unstructured":"Ko M-L, Peng P-H, Hsu S-Y, Chen C-F (2010) Dietary deficiency of vitamin E aggravates retinal ganglion cell death in experimental glaucoma of rats. Curr Eye Res 35:842\u2013849","journal-title":"Curr Eye Res"},{"key":"3773_CR39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/01.ijg.0000151882.07232.1d","volume":"14","author":"G-L Zhan","year":"2005","unstructured":"Zhan G-L, Camras CB, Palmberg PF, Toris CB (2005) Effects of marijuana on aqueous humor dynamics in a glaucoma patient. J Glaucoma 14:175\u2013177","journal-title":"J Glaucoma"},{"key":"3773_CR40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01.ijg.0000212260.04488.60","volume":"15","author":"I Tomida","year":"2006","unstructured":"Tomida I, Azuara-Blanco A, House H et al (2006) Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma 15:349\u2013353","journal-title":"J Glaucoma"},{"key":"3773_CR41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/bjo.2003.037671","volume":"89","author":"A Luksch","year":"2005","unstructured":"Luksch A, Rainer G, Koyuncu D et al (2005) Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma. Br J Ophthalmol 89:21\u201325","journal-title":"Br J Ophthalmol"},{"key":"3773_CR42","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00061198-199810000-00008","volume":"7","author":"JR Piltz","year":"1998","unstructured":"Piltz JR, Bose S, Lanchoney D (1998) The effect of nimodipine, a centrally active calcium antagonist, on visual function and macular blood flow in patients with normal-tension glaucoma and control subjects. J Glaucoma 7:336\u2013342","journal-title":"J Glaucoma"},{"key":"3773_CR43","doi-asserted-by":"crossref","first-page":"1586240","DOI":"10.3389\/fcell.2025.1586240","volume":"13","author":"N Rajakrishna","year":"2025","unstructured":"Rajakrishna N, Lim ST, Wang X, Wong TT (2025) Caspase-mediated pathways in retinal ganglion cell injury: a novel therapeutic target for glaucoma. Front Cell Dev Biol 13:1586240","journal-title":"Front Cell Dev Biol"},{"key":"3773_CR44","doi-asserted-by":"publisher","DOI":"10.17925\/USOR.2023.17.1.4","author":"P Ichhpujani","year":"2023","unstructured":"Ichhpujani P, Thakur S (2023) Idose TR sustained-release travoprost implant for the treatment of glaucoma. US Ophthalmic Rev. https:\/\/doi.org\/10.17925\/USOR.2023.17.1.4","journal-title":"US Ophthalmic Rev"},{"key":"3773_CR45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00061198-200604000-00009","volume":"15","author":"I McIlraith","year":"2006","unstructured":"McIlraith I, Strasfeld M, Colev G, Hutnik CM (2006) Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. J Glaucoma 15:124\u2013130","journal-title":"J Glaucoma"},{"key":"3773_CR46","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jamaophthalmol.2013.5059","volume":"131","author":"E Rulli","year":"2013","unstructured":"Rulli E, Biagioli E, Riva I et al (2013) Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA Ophthalmol 131:1573\u20131582","journal-title":"JAMA Ophthalmol"},{"key":"3773_CR47","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/0002-9394(73)90819-2","volume":"75","author":"MM Krasnov","year":"1973","unstructured":"Krasnov MM (1973) Laseropuncture of anterior chamber angle in glaucoma. Am J Ophthalmol 75:674\u2013678","journal-title":"Am J Ophthalmol"},{"key":"3773_CR48","first-page":"21","volume":"308","author":"M Detry-Morel","year":"2008","unstructured":"Detry-Morel M, Muschaert F, Pourjavan S (2008) MicropulseTM diode laser (810 nm) versus Argon laser trabeculoplasty in the treatment of open-angle glaucoma: comparative short-term safety and efficacy profile. Bulletin de la Soci\u00e9t\u00e9 Belge d\u2019\u2019Ophtalmologie 308:21","journal-title":"Bulletin de la Soci\u00e9t\u00e9 Belge d\u2019\u2019Ophtalmologie"},{"key":"3773_CR49","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0161-6420(98)91129-0","volume":"105","author":"MA Latina","year":"1998","unstructured":"Latina MA, Sibayan SA, Shin DH et al (1998) Q-switched 532-nm Nd: YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology 105:2082\u20132090","journal-title":"Ophthalmology"},{"key":"3773_CR50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/112067210601600116","volume":"16","author":"FS Weinand","year":"2006","unstructured":"Weinand FS, Althen F (2006) Long-term clinical results of selective laser trabeculoplasty in the treatment of primary open angle glaucoma. Eur J Ophthalmol 16:100\u2013104","journal-title":"Eur J Ophthalmol"},{"key":"3773_CR51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ophtha.2022.09.009","volume":"130","author":"G Gazzard","year":"2023","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D et al (2023) Laser in glaucoma and ocular hypertension (LiGHT) trial: six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology 130:139\u2013151","journal-title":"Ophthalmology"},{"key":"3773_CR52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.survophthal.2014.06.006","volume":"60","author":"MOM Wong","year":"2015","unstructured":"Wong MOM, Lee JWY, Choy BNK et al (2015) Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Surv Ophthalmol 60:36\u201350","journal-title":"Surv Ophthalmol"},{"key":"3773_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2025.2485223","author":"DC Amaral","year":"2025","unstructured":"Amaral DC, Guedes J, Moreira PHS et al (2025) A comparison of the 360\u00b0 versus 180\u00b0 of selective laser trabeculoplasty (SLT) in the treatment of open angle glaucoma (OAG) and ocular hypertension (OHT): a comprehensive systematic review and meta-analysis. Curr Eye Res. https:\/\/doi.org\/10.1080\/02713683.2025.2485223","journal-title":"Curr Eye Res"},{"key":"3773_CR54","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.3390\/biomedicines12102212","volume":"12","author":"P Thelen","year":"2024","unstructured":"Thelen P, B\u00f6hringer D, Keye P et al (2024) Selective laser trabeculoplasty after a previous glaucoma treatment. Biomedicines 12:2212","journal-title":"Biomedicines"},{"key":"3773_CR55","doi-asserted-by":"crossref","unstructured":"Gazzard G, Congdon N, Azuara-Blanco A, et al (2025) Randomized Non-Inferiority Trial of Direct Selective Laser Trabeculoplasty in Open-Angle Glaucoma and Ocular Hypertension: GLAUrious. Ophthalmology","DOI":"10.1016\/j.ophtha.2025.05.004"},{"key":"3773_CR56","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1442-9071.2011.02530.x","volume":"39","author":"M Dirani","year":"2011","unstructured":"Dirani M, Crowston JG, Taylor PS et al (2011) Economic impact of primary open-angle glaucoma in Australia. Clin Exp Ophthalmol 39:623\u2013632","journal-title":"Clin Exp Ophthalmol"},{"key":"3773_CR57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/bjophthalmol-2015-307515","volume":"100","author":"S Tsang","year":"2016","unstructured":"Tsang S, Cheng J, Lee JW (2016) Developments in laser trabeculoplasty. Br J Ophthalmol 100:94\u201397","journal-title":"Br J Ophthalmol"},{"key":"3773_CR58","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3928\/15428877-20090430-07","volume":"40","author":"M Goldenfeld","year":"2009","unstructured":"Goldenfeld M, Melamed S, Simon G, Ben Simon GJ (2009) Titanium:sapphire laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma. Ophthalmic Surg Lasers Imaging 40:264\u2013269. https:\/\/doi.org\/10.3928\/15428877-20090430-07","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"3773_CR59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/ICU.0b013e32835d9335","volume":"24","author":"K Ishida","year":"2013","unstructured":"Ishida K (2013) Update on results and complications of cyclophotocoagulation. Curr Opin Ophthalmol 24:102\u2013110","journal-title":"Curr Opin Ophthalmol"},{"key":"3773_CR60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/ceo.12360","volume":"43","author":"MCD Aquino","year":"2015","unstructured":"Aquino MCD, Barton K, Tan AMW et al (2015) Micropulse versus continuous wave transscleral diode cyclophotocoagulation in refractory glaucoma: a randomized exploratory study. Clin Exp Ophthalmol 43:40\u201346","journal-title":"Clin Exp Ophthalmol"},{"key":"3773_CR61","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.ophtha.2007.02.005","volume":"114","author":"PY Ramulu","year":"2007","unstructured":"Ramulu PY, Corcoran KJ, Corcoran SL, Robin AL (2007) Utilization of various glaucoma surgeries and procedures in Medicare beneficiaries from 1995 to 2004. Ophthalmology 114:2265\u20132270","journal-title":"Ophthalmology"},{"issue":"23\u201331","key":"3773_CR62","volume":"143","author":"SJ Gedde","year":"2007","unstructured":"Gedde SJ, Herndon LW, Brandt JD et al (2007) Surgical complications in the Tube Versus Trabeculectomy Study during the first year of follow-up. Am J Ophthalmol 143(23\u201331):e2","journal-title":"Am J Ophthalmol"},{"key":"3773_CR63","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/IJG.0000000000002013","volume":"31","author":"DS Grover","year":"2022","unstructured":"Grover DS, Kahook MY, Seibold LK et al (2022) Clinical outcomes of Ahmed ClearPath implantation in glaucomatous eyes: a novel valveless glaucoma drainage device. J Glaucoma 31:335\u2013339","journal-title":"J Glaucoma"},{"key":"3773_CR64","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/ICU.0b013e32834ff1e7","volume":"23","author":"H Saheb","year":"2012","unstructured":"Saheb H, Ahmed IIK (2012) Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol 23:96\u2013104","journal-title":"Curr Opin Ophthalmol"},{"key":"3773_CR65","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ophtha.2010.07.007","volume":"118","author":"TW Samuelson","year":"2011","unstructured":"Samuelson TW, Katz LJ, Wells JM et al (2011) Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology 118:459\u2013467","journal-title":"Ophthalmology"},{"key":"3773_CR66","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jcrs.2009.10.031","volume":"36","author":"AM Fea","year":"2010","unstructured":"Fea AM (2010) Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma: randomized double-masked clinical trial. J Cataract Refract Surg 36:407\u2013412","journal-title":"J Cataract Refract Surg"},{"key":"3773_CR67","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00347-018-0669-1","volume":"115","author":"M Lenzhofer","year":"2018","unstructured":"Lenzhofer M, Hohensinn M, Strohmaier C, Reitsamer HA (2018) Subconjunctival minimally invasive glaucoma surgery: methods and clinical results. Ophthalmologe 115:381\u2013387","journal-title":"Ophthalmologe"},{"key":"3773_CR68","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1167\/iovs.12-9570","volume":"53","author":"LJ Camras","year":"2012","unstructured":"Camras LJ, Yuan F, Fan S et al (2012) A novel Schlemm\u2019s canal scaffold increases outflow facility in a human anterior segment perfusion model. Invest Ophthalmol Vis Sci 53:6115\u20136121","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3773_CR69","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ophtha.2015.03.031","volume":"122","author":"N Pfeiffer","year":"2015","unstructured":"Pfeiffer N, Garcia-Feijoo J, Martinez-de-la-Casa JM et al (2015) A randomized trial of a Schlemm\u2019s canal microstent with phacoemulsification for reducing intraocular pressure in open-angle glaucoma. Ophthalmology 122:1283\u20131293","journal-title":"Ophthalmology"},{"key":"3773_CR70","first-page":"71","volume":"21","author":"SY Jea","year":"2012","unstructured":"Jea SY, Mosaed S, Vold SD, Rhee DJ (2012) Effect of a failed trabectome on subsequent trabeculectomy. J Glaucoma 21:71\u201375","journal-title":"J Glaucoma"},{"key":"3773_CR71","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ajo.2019.07.015","volume":"208","author":"G Reiss","year":"2019","unstructured":"Reiss G, Clifford B, Vold S et al (2019) Safety and effectiveness of CyPass supraciliary micro-stent in primary open-angle glaucoma: 5-year results from the COMPASS XT study. Am J Ophthalmol 208:219\u2013225","journal-title":"Am J Ophthalmol"},{"key":"3773_CR72","unstructured":"Ticiana De Francesco M, Ianchulev S New Supraciliary Interventions for Glaucoma"},{"key":"3773_CR73","first-page":"427","volume":"111","author":"D Laroche","year":"2019","unstructured":"Laroche D, Anugo D, Ng C, Ishikawa H (2019) Intra-scleral ciliary sulcus suprachoroidal microtube: making supraciliary glaucoma surgery affordable. J Natl Med Assoc 111:427\u2013435","journal-title":"J Natl Med Assoc"},{"key":"3773_CR74","unstructured":"Sheybani A, IK A (2015) Ab interno gelatin stent with mitomycin-C combined with cataract surgery for treatment of open-angle glaucoma: 1-year results. In: 2015 ASCRS ASOA Symposium and Congress"},{"key":"3773_CR75","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4103\/IJO.IJO_1072_24","volume":"72","author":"AN Bukke","year":"2024","unstructured":"Bukke AN, Midha N, Mahalingam K et al (2024) Outcomes of bent ab interno needle goniectomy with phacoemulsification in moderate to severe primary open angle glaucoma. Indian J Ophthalmol 72:1280\u20131284","journal-title":"Indian J Ophthalmol"},{"key":"3773_CR76","doi-asserted-by":"crossref","first-page":"1294651","DOI":"10.3389\/fopht.2024.1294651","volume":"4","author":"D Laroche","year":"2024","unstructured":"Laroche D, Adebayo A, Brown A et al (2024) Early cataract surgery and affordable Sinskey hook goniotomy in Black and Afro-Latino glaucoma patients: a 6-month retrospective study. Front Ophthalmol 4:1294651","journal-title":"Front Ophthalmol"},{"key":"3773_CR77","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/IJG.0000000000002598","volume":"34","author":"Y Song","year":"2025","unstructured":"Song Y, Ye X, Yang M et al (2025) Outcomes of phacogoniotomy for medically controlled and uncontrolled primary open angle glaucoma with cataract: a multicenter study. J Glaucoma 34:591\u2013597","journal-title":"J Glaucoma"},{"key":"3773_CR78","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajo.2023.08.002","volume":"256","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Yu P, Zhang Y et al (2023) Influence of goniotomy size on treatment safety and efficacy for primary open-angle glaucoma: a multicenter study. Am J Ophthalmol 256:118\u2013125","journal-title":"Am J Ophthalmol"},{"key":"3773_CR79","first-page":"157","volume":"20","author":"E Sanchez","year":"1996","unstructured":"Sanchez E, Schnyder CC, Sickenberg M et al (1996) Deep sclerectomy: results with and without collagen implant. Int Ophthalmol 20:157\u2013162","journal-title":"Int Ophthalmol"},{"key":"3773_CR80","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jcjo.2016.07.013","volume":"52","author":"R Conlon","year":"2017","unstructured":"Conlon R, Saheb H, Ahmed IIK (2017) Glaucoma treatment trends: a review. Can J Ophthalmol 52:114\u2013124","journal-title":"Can J Ophthalmol"},{"key":"3773_CR81","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cts.12660","volume":"13","author":"RM Lee","year":"2020","unstructured":"Lee RM, Bouremel Y, Eames I et al (2020) Translating minimally invasive glaucoma surgery devices. Clin Transl Sci 13:14\u201325","journal-title":"Clin Transl Sci"},{"key":"3773_CR82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10544-015-0028-9","volume":"18","author":"C-J Park","year":"2016","unstructured":"Park C-J, Yang D-S, Cha J-J, Lee J-H (2016) Polymeric check valve with an elevated pedestal for precise cracking pressure in a glaucoma drainage device. Biomed Microdevices 18:1\u20138","journal-title":"Biomed Microdevices"},{"key":"3773_CR83","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1167\/iovs.13-12626","volume":"55","author":"A Villamarin","year":"2014","unstructured":"Villamarin A, Roy S, Bigler S, Stergiopulos N (2014) A new adjustable glaucoma drainage device. Invest Ophthalmol Vis Sci 55:1848\u20131852","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3773_CR84","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/IJG.0000000000001471","volume":"29","author":"S Roy","year":"2020","unstructured":"Roy S, Villamarin A, Stergiopulos C et al (2020) Comparison between the eyeWatch device and the Ahmed valve in refractory glaucoma. J Glaucoma 29:401\u2013405","journal-title":"J Glaucoma"},{"key":"3773_CR85","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/IJG.0000000000001209","volume":"28","author":"S Roy","year":"2019","unstructured":"Roy S, Villamarin A, Stergiopulos C et al (2019) Initial clinical results of the eyeWatch: a new adjustable glaucoma drainage device used in refractory glaucoma surgery. J Glaucoma 28:452\u2013458","journal-title":"J Glaucoma"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03773-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03773-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03773-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:04:01Z","timestamp":1766167441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03773-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3773"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03773-2","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial of non-financial interests that are directly or indirectly related to the work submitted for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"381"}}